Alira Health

Alira Health

TerSera Therapeutics to sponsor “NET Cancer Health Storylines” by Alira Health and Carcinoid Cancer Foundation to support patients suffering from Carcinoid Syndrome Diarrhea

News
Published on:
January 23, 2023

We are pleased to announce TerSera Therapeutics’ sponsorship with the Carcinoid Cancer Foundation (CCF) and Alira Health to expand and optimize a holistic patient journey digital platform for patients with Neuroendocrine Tumors and Carcinoid Syndrome.

This patient support program is a powerful collaboration between TerSera Therapeutics, Carcinoid Cancer Foundation, and Alira Health. We are excited for Health Storylines to power this high-touch, high-tech, and high-science support for patients with NET Cancer and Carcinoid Syndrome."
Jennifer Lannon Director, Partnerships and Business Development, Patient Advocacy, Alira Health

To support patients in coping with the impact NETs have on their quality of life and collaborate with their care team on treatment decisions, Alira Health and the Carcinoid Cancer Foundation have collaborated since 2015 to build “NET Cancer Health Storylines,” a customized version of the Health Storylines™ app that makes it easy for patients to record their symptoms, nutritional concerns, moods, medication and more. The NET Health Storylines app provides patients with resources developed by NET experts. Specific tools include a Stool Diary, NET Nutrition tool, Medication tracker, and additional educational resources. The app is available for download at the NET Cancer Health Storylines website or through the Apple App Store or Google Play.

“We are grateful for this support from TerSera to continue to enhance the NET Health Storylines platform to distribute meaningful educational content to NETs patients. The resources available through this platform are important tools in supporting NET patients throughout their journey,” said Keith Warner, Chief Executive Officer of the Carcinoid Cancer Foundation.

“Collaborating with CCF and the NET Cancer Health Storylines platform is a fantastic opportunity for us to support patients with Carcinoid Syndrome Diarrhea beyond our existing clinical nurse educator program. We are also looking forward to learning from patients how we can continue to support them better on their journey,” said Pamela Gaytan, Executive Director, Clinical Nurse Educators and Patient Advocacy of TerSera Therapeutics.

“This patient support program is a powerful collaboration between TerSera Therapeutics, Carcinoid Cancer Foundation, and Alira Health. We are excited for Health Storylines to power this high-touch, high-tech, and high-science support for patients with NET Cancer and Carcinoid Syndrome,” adds Jennifer Lannon, Director, Partnerships & Business Development, Patient Advocacy of Alira Health.

About Alira Health

Alira Health is a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. From development to medical care, Alira Health complements the expertise of its Pharma, Biotech, and MedTech clients with a full spectrum of services across their entire solutions lifecycle.

About TerSera Therapeutics

TerSera Therapeutics acquires, develops, and markets specialty pharmaceutical products with a focus on oncology and non-opioid pain. Its mission is to provide products which truly make a difference for patients. For more information about TerSera Therapeutics, please visit www.tersera.com.

About Carcinoid Cancer Foundation

The Carcinoid Cancer Foundation is the oldest nonprofit carcinoid and neuroendocrine cancer organization in the United States, founded in 1968. The mission of the foundation is to increase awareness and educate the general public and healthcare professionals regarding neuroendocrine tumors (NETs), to support NET cancer patients and their families, and to serve as patient advocates. Visit the CCF website for more information, www.carcinoid.org.

Related news

News May 6, 2024
Alira Health’s CDD Advises TVM Capital Healthcare Investment in neurocare Group AG
We are pleased to have been a Commercial Due Diligence advisor for an investment by TVM Capital Healthcare into neurocare group AG. The Munich-based leader in personalized mental health(...)
CDD Digital Therapeutics
Articles May 3, 2024
Successful Patient Advisory Boards: What Sponsors Need to Know
Discover five essential keys to a successful Patient Advisory Board (PAB) that can provide actionable feedback to guide you on all stages of development.
Patient Centricity Patient Engagement
Events April 24, 2024
MGFA National Patient Conference 2024
We are pleased to share that we will be participating in MGFA National Patient Conference 2024 as speakers and exhibitors.
Digital Health Innovation Myasthenia Gravis (MG) Patient Engagement Rare Disease
Events April 10, 2024
European Patients as Partners in Clinical Research 2024
Join our panel at the European Patients as Partners event: "The Impact of Patient Involvement Along the Product Lifecycle."
Patient Centricity Patient Engagement
Case Studies March 26, 2024
Pharma Company Overcomes Launch Challenges with Patient-Centric Strategy
Our patient engagement team helped this pharma client identify the drivers behind the challenges they faced with their product launch.
Patient Centricity Patient Engagement Pharma
Articles March 13, 2024
Strategic Patient Engagement as a Game Changer for Your Product Success
This FAQ addresses popular questions about how to make patient engagement the core of a product development and commercialization strategy.
Patient Centricity Patient Engagement
Case Studies March 12, 2024
Pharma Company Adopts a Patient-Centric Value Proposition for Regulatory and Payer Dossier
A pharma company had a wealth of patient data on a product in development and they wanted to create a long-term strategy that would create a continuity of patient engagement across(...)
Patient Centricity Patient Engagement Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.